Ignite Creation Date:
2024-05-05 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00517530
Status:
COMPLETED
Last Update Posted:
2016-10-11
First Post:
2007-08-16
Brief Title:
A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen CD20 Malignant Disease GAUGUIN
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Organization Data
Organization:
Hoffmann-La Roche
Class:
INDUSTRY
Study ID:
BO20999
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Hoffmann-La Roche
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None